Luca Issi
Stock Analyst at RBC Capital
(4.30)
# 424
Out of 5,044 analysts
206
Total ratings
51.59%
Success rate
16.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Downgrades: Sector Perform | $21 → $14 | $14.79 | -5.34% | 6 | Oct 28, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $435 → $500 | $478.58 | +4.48% | 28 | Sep 19, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $70 → $80 | $72.99 | +9.60% | 9 | Sep 4, 2025 | |
| ARGX argenx SE | Initiates: Outperform | $850 | $829.83 | +2.43% | 1 | Aug 25, 2025 | |
| RGNX REGENXBIO | Maintains: Outperform | $21 → $17 | $13.62 | +24.82% | 10 | Aug 8, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $40 → $38 | $39.48 | -3.75% | 9 | Aug 8, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $210 → $230 | $203.23 | +13.17% | 3 | Aug 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Sector Perform | $38 → $42 | $65.72 | -36.09% | 14 | Aug 5, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Sector Perform | $4 → $5 | $9.65 | -48.19% | 1 | Jul 30, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $25 → $23 | $24.17 | -4.84% | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $4.24 | -5.66% | 8 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.23 | +713.01% | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $18 | $29.78 | -39.56% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $28 | $26.66 | +5.03% | 17 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $9.84 | +103.25% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $95 | $39.58 | +140.02% | 7 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $0.63 | +217.91% | 6 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $11.55 | +47.19% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $8.87 | +46.56% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $12.27 | +185.25% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $26 | $26.73 | -2.73% | 7 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $52.67 | +32.90% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $67.92 | -64.66% | 6 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $36.16 | +57.63% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $67 | $70.00 | -4.29% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $3.25 | +23.08% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $35.31 | +118.07% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $7.62 | +96.85% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.45 | +471.43% | 5 | Aug 7, 2024 |
Intellia Therapeutics
Oct 28, 2025
Downgrades: Sector Perform
Price Target: $21 → $14
Current: $14.79
Upside: -5.34%
Alnylam Pharmaceuticals
Sep 19, 2025
Maintains: Outperform
Price Target: $435 → $500
Current: $478.58
Upside: +4.48%
Ionis Pharmaceuticals
Sep 4, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $72.99
Upside: +9.60%
argenx SE
Aug 25, 2025
Initiates: Outperform
Price Target: $850
Current: $829.83
Upside: +2.43%
REGENXBIO
Aug 8, 2025
Maintains: Outperform
Price Target: $21 → $17
Current: $13.62
Upside: +24.82%
Arrowhead Pharmaceuticals
Aug 8, 2025
Maintains: Outperform
Price Target: $40 → $38
Current: $39.48
Upside: -3.75%
Ascendis Pharma
Aug 8, 2025
Maintains: Outperform
Price Target: $210 → $230
Current: $203.23
Upside: +13.17%
CRISPR Therapeutics AG
Aug 5, 2025
Maintains: Sector Perform
Price Target: $38 → $42
Current: $65.72
Upside: -36.09%
Fulcrum Therapeutics
Jul 30, 2025
Maintains: Sector Perform
Price Target: $4 → $5
Current: $9.65
Upside: -48.19%
Dyne Therapeutics
Jul 29, 2025
Maintains: Outperform
Price Target: $25 → $23
Current: $24.17
Upside: -4.84%
May 15, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $4.24
Upside: -5.66%
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $1.23
Upside: +713.01%
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $29.78
Upside: -39.56%
May 2, 2025
Maintains: Sector Perform
Price Target: $32 → $28
Current: $26.66
Upside: +5.03%
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $9.84
Upside: +103.25%
Mar 19, 2025
Maintains: Outperform
Price Target: $105 → $95
Current: $39.58
Upside: +140.02%
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.63
Upside: +217.91%
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $11.55
Upside: +47.19%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $8.87
Upside: +46.56%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $12.27
Upside: +185.25%
Feb 26, 2025
Maintains: Sector Perform
Price Target: $24 → $26
Current: $26.73
Upside: -2.73%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $52.67
Upside: +32.90%
Jan 21, 2025
Reiterates: Outperform
Price Target: $24
Current: $67.92
Upside: -64.66%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $36.16
Upside: +57.63%
Jan 21, 2025
Reiterates: Outperform
Price Target: $67
Current: $70.00
Upside: -4.29%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $3.25
Upside: +23.08%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $35.31
Upside: +118.07%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $7.62
Upside: +96.85%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $2.45
Upside: +471.43%